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Rapid detection of sentinel lymph node metastases in different techniques
and comparison in low-grade breast carcinomas
Detección rápida de metástasis en ganglio centinela y comparación
de diferentes técnicas en carcinomas de mama de bajo grado
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Summary
Introduction: The role of sentinel node biopsy has revolutionized breast cancer treatment. This determination
reduces the mobility of a complete axillary lymphadenectomy. The aim of our study is to analyze the value of sentinel
node in low-grade histological breast tumors, studied with hematoxylin and eosin techniques, Immunohistochemistry,
and molecular chain reaction in real-time quantitative polymerase (RT-PCR).
Materials and methods: In a pilot study we studied a total of 21 patients with histological diagnosis of mucinous
carcinoma, adenoid cystic carcinoma, and medullar carcinoma that underwent the sentinel node technique. Once the
lymph node was removed, it was sent to pathology, where it was fragmented and evaluated, using between 25% and
50% of the lymph node for molecular biology laboratory studies.
Results: The sentinel nodes studied were 32, corresponding to the 21 patients. Of the 32 lymph nodes analyzed,
29 (90.6%) were negative on histopathological examination and the molecular identification, 2 (6.2%) were positive
in both techniques and 1 (3.125%) lymph node was positive with quantitative RT-PCR and negative in histology
(H&E), which – subsequently by immunohistochemistry (IHC) – was diagnosed as isolated tumor cells (ITC).
Conclusion: When comparing the techniques of hematoxylin and eosin, immunohistochemistry, and molecular
RT-PCR technique, we found greater sensitivity of molecular techniques; this can reduce the false negative and
improve diagnosis of sentinel node metastases. Patients with low histological grade carcinomas have high survival
rates, less aggressive tumor behavior, and reduced lymph node at diagnosis.
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Immunohistochemistry; Lymph node excision.
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Resumen
Introducción: El rol de la biopsia del ganglio centinela ha revolucionado el tratamiento del cáncer de mama.
Tomar esta determinación disminuye la morbilidad de una linfadenectomía axilar completa. El objetivo del estudio
es analizar el valor del ganglio centinela en los tumores de mama de tipo histológico de bajo grado y estudiarlos con
las técnicas de hematoxilina y eosina, inmunohistoquímica y molecular de reacción en cadena de la polimerasa en
tiempo real cuantitativa (RT-PCR).
Material y métodos: En un estudio piloto se estudiaron 21 pacientes con diagnóstico histológico de carcinoma
mucinoso, metaplásicos o adenoide quístico a quienes se les realizó la técnica del ganglio centinela. Una vez extraído
el ganglio se envió a anatomía patológica, donde se fragmentó y evaluó. Para el estudio en el laboratorio de biología
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molecular se utilizó entre 25% y 50% del ganglio.
Resultados: Se estudiaron 32 ganglios centinelas,
correspondientes a 21 pacientes; 29 (90.6%) fueron nega-
tivos en el examen histopatológico y en la determinación
molecular, 2 (6.3%) positivos en ambas técnicas y en 1
(3.1%) hubo discrepancia en el diagnóstico, éste fue
positivo con la RT-PCR cuantitativa y negativo en el
estudio histológico (H&E), el cual, por inmunohisto-
química (IHC), se diagnosticó como células tumorales
aisladas (CTA).
Conclusión: Cuando se compararon las técnicas de
hematoxilina y eosina, inmunohistoquímica y la técnica
molecular RT-PCR cuantitativa, se comprobó mayor
sensibilidad en la técnica molecular, lo que permite dismi-
nuir los falsos negativos y tener un mejor diagnóstico de
las metástasis en los ganglios centinelas. Las pacientes
con carcinomas de tipo histológico de bajo grado tienen
una alta sobrevida, un comportamiento tumoral menos
agresivo y menor compromiso ganglionar en el momento
del diagnóstico.
Palabra clave: Metástasis linfática; Neoplasias de la
mama; Reacción en cadena de la polimerasa; Biopsia;
Inmunohistoquímica; Excisión del ganglio linfático.
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Prior to deploying the surgical technique of the
sentinel node, breast cancer treatment included com-
plete axillary dissection for determination of axillary
metastases. Currently, the lymph node metastases are
the most important predictive factor and studies on
the sentinel node technique have facilitated advancing
in its detection and conducting adequate locoregional
control1.
The anatomopathological study of the lymph
nodes posterior to a complete axillary dissection,
where two or three sections were made of each node
and these were stained with hematoxylin and eosin
(H&E), was a routine procedure that did not permit
the exhaustive study of all the nodes, nor did it direct
diagnostic efforts to one or two of them specifically2.
The sentinel node is defined as the first drainage
node of the breast, which is detected via nuclear
medicine techniques and/or dye. This determination
has diminished the morbidity of a complete axillary
lymphadenectomy and has revolutionized breast
cancer treatment during the last decade2. It was also
established which were the candidate patients for the
technique, women with diagnosis of breast cancer in
stages I and II, with tumors smaller than 3 cm and
without axillary compromise on clinical exam. The
study of the sentinel node has diminished lympha-
denectomies by 60% at these stages3.
Intraoperative exploration of the sentinel node
with routine techniques (H&E) was presented as a
result of continuous development of the analysis of
the sentinel node and it was designed to increase
benefits for patients and turned surgery into a real
possibility. These intraoperative methods, like imprint
cytology or frozen biopsy, depend on the expertise of
the pathologist and are not standardized, which
produces a considerable number of false negatives,
so that a significant number of micrometastases are
also detected later through postoperative diagnostic
methods like immunohistochemistry (IHC)4.
Patients with negative diagnosis by frozen biopsy
with posterior positive result through immuno-
histochemistry methods needed to be subjected to
surgical re-interventions that could have been avoided.
With the molecular diagnostic analysis (real time
PCR multiplex) a new diagnostic dimension has been
created. Unlike conventional imprint cytology and
frozen section or immunohistochemistry methods,
the molecular method admits complete lymph node
analysis and, consequently, permits making a final
decision within the time frame of surgical intervention.
The rates of false negatives vary from 5% to 45%
with hematoxylin and eosin. Consequently, a signi-
ficant number of patients must be subjected to re-
surgical intervention. Instead, evaluations with the
molecular method have shown specificity and
sensitivity above 96% compared to exhaustive
postoperative analyses of alternate sections of lymph
node tissue5,6.
This study sought to compare the molecular
technique (real-time PCR multiplex) with hematoxylin
and eosin and immunohistochemistry in detecting
metastasis in the sentinel node in low-grade tumors.
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Patients and methods
A prospective study and prognosis from
November 2004 to May 2010 was conducted at the
Hospital Clínico San Carlos de Madrid, in Madrid and
approved by the institutional ethics committee.
The total population studied was made up of 348
patients with diagnosis of invasive or micro-invasive
breast cancer, candidates for the sentinel node
technique, of which 21 fulfilled the inclusion criteria:
having a histological diagnosis of low-grade carcino-
ma according to WHO criteria in stages I and II
(smaller than 3 cm), not presenting clinical axillary
compromise, satisfactory migration of the radio-
isotope, interoperative imprint biopsy and frozen
biopsy with H&E, and authorized informed consent.
The study did not include patients with morbid
obesity, prior radiotherapy, unsatisfactory migration
of the radioisotope, with over five sentinel nodes, or
those with mixed tumors.
Method. Fragments of the sentinel node selected
for RT-PCR could not have been used in the frozen
biopsy; this lymph node was randomly distributed
according to size, 50% to 75% for pathological
anatomy, and between 25% and 50% for the molecular
technique, transported to the molecular biology
laboratory in guanidine solution (RNA STAT-60).
Molecular biology laboratory. The technique
used determines Mammaglobin A and CK-19 via
RT-PCR through GeneSearch TM Breast Lymph
Node; a quantitative test was performed for rapid
detection of clinically relevant metastases (>0.2 mm)
in the lymph node tissue removed and analyzed in the
Smart Cycler equipment. This method was designed
to make rapid amplification of nucleic acids and uses
mRNA from the genes to be studied. With this
equipment, the determination was conducted in 20
minutes.
Quantitative RT-PCR was carried out with a
homogenous sample of fresh lymph node tissue;
three gene markers were included – Mammaglobin
A, CK-19 and an internal control gene, porpho-
bilinogen deaminase (PBGD), and the «housekeeping
gene» found in all genes.
The quantitative RT-PCR technique followed these
steps: degradation of the lymph node tissue,
homogenization and purification of RNA, and then
retrotranscription (RNA to DNA) was carried out
with GeneSearchTM Breast Lymph Node equipment
and DNA amplification (real time PCR multiplex) in
Smart Cycler equipment (Figure 1). Therein, the
interpretation of the results was carried out according
to threshold values, thus: Mammaglobin A <31, CK
19 <30, PBGD <36 (Figures 2 and 3).
Internal control. Detects mRNA from a gene
expressed constitutively in PBGD lymph nodes;
such must always be positive to avoid false negatives.
External control. The positive control only has
Figure 1. Smart Cycler equipment, where DNA amplification is performed and the results are analyzed
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Figure 2. Note the positive simple for mammaglobin A, negative for CK-19,
and positive PBGD (internal control)
Figure 3. Note the negative sample for mammaglobin, CK-19 and
positive for PBGD (internal control)
Mammaglobin A and CK19 cancer markers; the
negative control only contains PBGD, which must
be included in each of the amplifications.
The value of the control is determined when the
fluorescent signal surpasses a defined threshold. If
the external controls are valid, then the genetic value
of the sample is compared to the threshold values of
the controls that are specific of each marker.
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Interpretation
1. If the Ct value of one or both genetic markers is
inferior to the threshold value, the sample is
determined positive.
2. If the Ct value of both genetic markers is superior
to the threshold value and the internal control is
inferior to the threshold value, the sample is
determined negative.
3. If the Ct value of the internal control is superior to
the threshold value, the simple is determined not
valid.
4. If the external controls are not valid, it is determined
that the whole amplification process is not valid;
all the samples of that run must be repeated.
Results
The mean age of the patients was 63 years, with a
minimum of 41 years and a maximum of 85 years.
The histological type most often found during a 67
month period was mucinous carcinoma in 11 cases,
medullar carcinoma in nine, and one case with diag-
nosis of adenoid cystic carcinoma.
Of the 11 cases of mucinous carcinoma found,
eight were tumor grade II, two cases grade I, and one
case grade III, with tumor size ranging between 0.6
and 2 cm. The Immunohistochemical study of the
hormone receptors corresponds to 10 cases positive
estrogen and 1 negative case, 9 cases positive proges-
terone, and 2 negative cases. The proliferation index
studied with Ki-67 in seven cases was less than 5%;
three cases at 10% and only one case at 50%. In the
11 cases the Her2 neu oncogene was negative. None
of the 11 cases has had tumor recurrence, with
survival at five years of nine patients and two deaths
by another cause different from breast tumor. The
molecular study was coincidentally the quantitative
RT-PCR and with IHC in two cases of micro-
metastases (Table 1).
Of the nine medullar carcinomas found, seven
had tumor grade III, two cases were grade II, with
tumor size ranging between 0.3 and 3 cm. The
Immunohistochemical study of the hormone
receptors corresponds to one case of positive estrogen
and eight negative cases, seven cases positive
progesterone and two negative cases. The proliferation
index studied via Ki-67 in two cases was at 15%, in
four cases at 30 and 40%, and three 3 cases were at 60
and 80%. The Her2 neu oncogene was negative in
eight cases and one case was confirmed positive with
Fluorescent In Situ Hybridization (FISH). One case
showed local tumor recurrence where the molecular
study was positive via quantitative RT-PCR and via
IHC this case was diagnosed as isolated tumor cells
(Table 2), one patient died of causes different from
breast tumor, with survival at 5 years of the remaining
eight patients.
Only one case involved cystic adenoid type breast
carcinoma with grade-I tumor, size at 0.6 cm, with
positive hormone receptors, proliferation index of
2%, with negative Her2 neu, without tumor recurrence
and alive after two years of follow up (Table 3).
In low-grade carcinomas, negativity of the sentinel
node was observed at 85.7% (18 cases) and positivity
at 14.2% (three cases). Survival at five years is of 17
patients, corresponding to 80.9% and one patient
remains alive after two years of follow up.
Three patients died of causes different from breast
cancer. Only one patient endured tumor recurrence
after four years of follow up, which corresponds to
4.7% of this group of patients.
Of the 32 lymph nodes analyzed, 29 (90.6%) were
negative on histopathological exam and on molecular
determination; two (6.2%) were positive in both
techniques and diagnostic discrepancy was noted in
one (3.1%), which was positive with RT-PCR and
negative in the histological study, which was thereafter
– via IHC – diagnosed as isolated tumor cells.
Discussion
Medullar mammary, mucinous, and cystic adenoid
carcinomas are low grade. It is uncommon to find in
these axillary metastases and they usually have good
prognosis. It was, thus, noted in this series where of
the 32 nodes analyzed, 90.6% were negative through
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the three techniques evaluated: quantitative RT-PCR,
H&E, and IHC. This is reflected on the high free
survival of the disease and on the low mortality
caused by the tumor. In this article, the rate of false
negatives by using H&E, IHC, and quantitative RT-
PCR is zero due to the increased sensitivity through
the molecular technique. On a review of 11 studies,
the rate of false negatives fluctuated between 0% and
33%7,8.
The number of positive axillary lymph nodes is
important in infiltrating breast cancer. Survival,
recurrence, speed of recurrence appearance, and
treatment failure are related to the number of positive
axillary lymph nodes. Without evidence of lymph
node metastasis, survival at five years is at 87%, while
the presence of some positive node diminishes it to
75%; by having one to three lymph nodes involved,
survival is at 64.5% and with 4 or more positive
lymph nodes, survival falls to 34.5%9. In this series,
two cases (6.3%) were positive through the three
techniques evaluated (quantitative RT-PCR, H&E,
and IHC) and one case was positive through
quantitative RT-PCR and negative through H&E.
Thus, the sensitivity of this molecular technique also
Table 1
Variables studied in the mucinous carcinoma
Variables Value
Mucinous carcinomaTumor grade according to
Nottingham Grading
Mucinous carcinoma, tumor size in cm
Mucinous carcinoma
Hormone receptors
Positive value according to the Allred index
Proliferation index (Ki 67)
Her 2 neu
Pre-surgical treatment
Postsurgical treatment
Nodal affectation studied with H&E, IHC,
and RT-PCR
Lymphadenectomy
Tumor recurrence
Death:
1: Toxicity and 1: Ovarian carcinoma
Survival at 5 years
Grade I: 2
Grade II: 8
Grade III: 1
0.6 to 2 cm
Positive estrogen receptor: 10
Negative estrogen receptor: 1
Positive progesterone receptor: 9
Negative progesterone receptor: 2
1% to 5%: 7
10%: 3
50%: 1
Negative Herceptest: 11
Negative FISH: 11
0
11
Yes: 2 (1/2 and 1/1)
No: 9
Yes: 2
Both lymphadenectomies 1/7 and 2/6
No: 11
No: 9
Yes: 2
total: 9
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Table 2
Variables studied in medullar carcinoma
Variables            Value
Medullar carcinoma
Tumor grade according to Nottingham Grading
Tumor size in cm
Hormone receptors
Positive value according to the Allred index
Proliferation index (Ki 67)
Her 2 neu
Pre-surgical treatment
Postsurgical treatment
Nodal affectation studied with H&E, IHC,
and RT-PCR
Lymphadenectomy
Tumor recurrence
Death: Death by toxicity
Survival at 5 years
Grade I: 0
Grade II: 2
Grade III: 7
0.3 to 3 cm
Positive estrogen receptor: 1
Negative estrogen receptor: 8
Positive progesterone receptor: 7
Negative progesterone receptor: 2
15%: 2
30-40%: 4
60-80%: 3
Negative Herceptest: 9
Negative FISH: 8
Positive FISH: 1
0
9
Yes, positive by RT-PCR
IHC: isolated tumor cells
No: 8
No: 9
Yes:1
No:8
Local recurrence
No: 8
Yes: 1
Total: 8
agrees with that of IHC. Upon studying the discordant
case with IHC, the presence of isolated tumor cells
(ITC) was proved, which shows high precision in
detecting tumor mRNA in quantitative RT-PCR. On
follow up of this patient, tumor recurrence was noted
after four years of surgery, which suggests that this
condition (ITC) is a negative predicting factor in
tumor evolution, but more studies are rendered to
clarify the management of these patients.
It has been published that patients with
micrometastases studied in serial microscopic sec-
tions, and which are smaller than 2 mm, have a
survival comparable to patients without lymph node
metastasis10.
A prospective study by the international breast
cancer study group in Milan, studied the ipsilateral
axillary nodes considered negative. Serial sections
were made and after the systematic histological study,
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Table 3
Variables studied in the cystic adenoid carcinoma
Variables Value
Cystic adenoid carcinoma
Tumor grade according to Nottingham Grading
Tumor size in cm
Hormone receptors
Positive value according to the Allred index
Proliferation index (Ki 67)
Her 2 neu
Pre-surgical treatment
Postsurgical treatment
Nodal affectation studied with H&E, IHC, and RT-
PCR
Tumor recurrence
Death:
Survival at 2 years
Grade I: 1
0.6 cm
Positive estrogen receptor: 1
Positive progesterone receptor: 1
2%: 1
Negative Herceptest: 1
Negative FISH: 1
0
1
No: 1
No: 1
No: 1
Total: 1
micrometastases were found in a range from 9% to
20%; these patients with micrometastases had less
time of survival free of the disease and global survival
of the disease after five years than those whose nodes
remained negative after studying them via serial
sections11.
The Immunohistochemical and molecular
methods for the diagnosis of metastases hidden in the
axillary lymph nodes reveal that patients have a
higher recurrence index and worst survival rates
especially in high-grade carcinomas12. There were
only three such cases in the current series.
The macroscopic size of the infiltrating primary
malignant neoplasms is also a relevant prognostic
factor. There is direct relationship between tumor
size and axillary lymph node metastases. In tumors
smaller than 1 cm, there is metastasis at 26%, if the
tumor is bigger than 10 cm, there is metastasis at 78%.
A tumor with maximum 2 cm diameter has better
prognosis and survival rate, as long as it is compared
to bigger tumors13. In this series, tumor size is not
greater than 3 cm; hence, the lymph node compromise
found is only at 3.2%.
Since the work by Mason et al.14 in 1983, which
determined the expression of progesterone (PR) and
estrogen (ER) of all incidents of breast cancer between
1976 and 1980 in the city of Auckland (1,136 cases)
the clinical importance of the positivity for the
expression of ER and PR is accepted. In this study it
was seen that when both receptors were positive,
survival was greater than when they were negative;
said effect was proven in the absence of hormone
treatments now available to block the replication
activity induced by female steroids15. Nowadays, it is
accepted as a molecular prognostic factor in localized
disease. In our series, in the three tumor types, the
proportion of positivity for estrogen and progesterone
is predominant.
Regarding the HER-2 neu oncogene, such is
expressed at low concentrations in diverse normal
cells and are over-expressed in various types of
cancer. In general, this fact is caused by genetic
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amplification or by an increase in the number of
erbB-2 genes in the nucleus. This over-expression
plays a role in tumor progression; elevated titles are
produced of cell growth and oncogenic trans-
formation.
From the practical point of view, the significance
of the HER-2 neu oncogene in breast cancer is
multiple: breast cancer evolves from the non-invasive
premalignant lesion (in situ carcinoma) to the
metastatic carcinoma and passes the localized stages.
It is possible to find over-expression of HER-2 neu
in all stages of breast cancer, but it has not been found
in benign breast lesions; this suggests that the gene
does not amplify prior to a real malignant state16. In
the current series, 21 patients do not show the over-
expression of the Her-2 neu gene, upon study through
immunohistochemistry (Herceptest) and through
fluorescent in situ hybridization (FISH), which is
coherent with the low-grade histological types studied.
The proliferation index studied with the Ki 67
antigen permits identifying the proliferating cells
within the tumor and the positivity is correlated to the
grade of tumor differentiation, vascular invasion,
lymph node metastases and it is in inverse proportion
to the existence of hormone receptors, as observed in
the tumors we have studied in this series.
The advent of new techniques in pathological
anatomy like immunohistochemistry (IHC) has
increased the sensitivity in detecting micrometastases
(10-20%), against H&E stain5. The RT-PCR molecular
technique has increased sensitivity from 84 to 93%,
and specificity from 95% to 98%, compared to H&E
and IHC6.
This study compared the three techniques, reason
for which the node was fragmented. Even so, there
is high agreement. This has made the molecular
technique known with great reliability, which is why
currently the study is conducted of 100% of the
sentinel node, while with H&E a fragment of the
node is studied in the intraoperative. This has impact
upon the survival, time free of the disease, therapeutic
management, and quality of life of patients with
breast cancer.
Conclusions
• This series compared three study techniques of
the sentinel node (hematoxylin and eosin,
immunohistochemistry, and molecular) and a high
correlation was found.
• The molecular technique differentiates between a
micro- or macro-metastasic mass and the lymph
node and permits the surgeon to make a definitive
decision during the intervention.
• Patients with low-grade, histological-type carci-
nomas have high survival rates, less aggressive
tumor behavior, and lower lymph node commit-
ment during diagnosis and this was the case for the
patients in this series.
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